S&P Futures
4,170.00 -21.50 (-0.51%) Dow Futures
34,106.00 +9.00 (+0.03%) Nasdaq Futures
12,663.25 -183.50 (-1.43%) Russell 2000 Futures
2,007.00 -0.90 (-0.04%) Crude Oil
75.62 -0.26 (-0.34%) Gold
1,929.10 -1.70 (-0.09%)
International Stem Cell Corporation (ISCO)
Chart Events
Performance Outlook
| Previous Close | 0.2200 |
| Open | 0.2000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.2000 - 0.2000 |
| 52 Week Range | 0.1100 - 0.5400 |
| Volume | |
| Avg. Volume | 4,178 |
| Market Cap | 1.601M |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0390 |
| Earnings Date | Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ISCO
Related Research
- INTERNATIONAL STEM CELL CORPORAAnalyst Report: Thermo Fisher Scientific Inc.Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2022 (revenue figures include some cross-segment revenue): analytical technologies (15% of sales); specialty diagnostic products (10%); life science solutions (30%); and lab products and services, which includes CRO services (51%).RatingFair ValueEconomic Moat2 days agoMorningstar
- ACCESSWIRE
International Stem Cell Corporation Announces Strong Financial Results for the Quarter Ended March 31, 2022
SAN DIEGO, CA / ACCESSWIRE / May 17, 2022 / International Stem Cell Corporation (OTC PINK:ISCO) (www.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and financial results for the three months ended March 31, 2022.
- ACCESSWIRE
International Stem Cell Corporation Announces 2021 Fourth Quarter and Year-End Results
SAN DIEGO, CA / ACCESSWIRE / March 30, 2022 / International Stem Cell Corporation (OTCQX:ISCO) (www.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ending on December 31, 2021.
